iiinova — where your digital self keeps evolving

Axel Schmidt @axel-schmidt.bsky.social · 25/02/2026

I was just reading this article which is very nicely written and demonstrates how to use a SCN5A variant as an instrument to study the effect of sodium channel blockage

040

Axel Schmidt @axel-schmidt.bsky.social · 20/02/2026

We did not yet check, I thought it could be interesting to do this. I guess there are not so many people that were recruited/ genome sequenced when they got Rituximab or CAR treatment in UK Biobank or All of Us, due to their recruitment strategy (& time period for UKBB: 2006-2010).

020

Axel Schmidt @axel-schmidt.bsky.social · 20/02/2026

Interesting fact about Rituximab I did not know. One would think that Rituximab would decrease EBV infected B memory cells as it is used against PTLD I guess. One might still retrieve the amount of EBV reads in people treated with Rituximab.

110

Axel Schmidt @axel-schmidt.bsky.social · 20/02/2026

Hi Kilian, in Fig 4f we only show the P-value independent of effect direction. To see the effect direction you have to go to table S19. There you can see that we also have a negative association between GRS for EBVread+ and IBD. Best!

120

Reposted by Axel Schmidt

Kerstin Ludwig @kuludwig.bsky.social · 19/02/2026

🖨️ Hot off the press 🍾 : I am super excited to share that our article on the host control of persistent EBV infection has just been published in Nature Magazine, in an accelerated article preview version: rdcu.be/e4Lg8

rdcu.be

Host control of persistent Epstein–Barr virus infection

Nature - Host control of persistent Epstein–Barr virus infection

32614

Reposted by Axel Schmidt

Kerstin Ludwig @kuludwig.bsky.social · 22/07/2025

🔔Paper alert! Extremely excited to share a preprint from our lab! Spearheaded by @axel-schmidt.bsky.social, a super talented medical & computational geneticist, we studied latent Epstein-Barr virus (EBV) infection at population-scale. Interested in how this works & what we found? Read along! 👇

12312